Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
J Dtsch Dermatol Ges
; 8(1): 65-6, 2010 Jan.
Article
em En, De
| MEDLINE
| ID: mdl-20096063
ABSTRACT
In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Guias de Prática Clínica como Assunto
/
Medicina Baseada em Evidências
/
Dermatologia
/
Anticorpos Monoclonais
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
De
/
En
Ano de publicação:
2010
Tipo de documento:
Article